{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T12:10:35Z","timestamp":1759407035221,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010059","name":"University Of Nigeria Nsukka","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008895","name":"Tertiary Education Trust Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.vaccine.2023.09.046","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T03:13:06Z","timestamp":1696648386000},"page":"6820-6823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neutralizing anti-polio antibody titre in newborn babies in post-polio eradication period in Nigeria"],"prefix":"10.1016","volume":"41","author":[{"given":"Maduka D.","family":"Ughasoro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ifeyinwa","family":"Nnakenyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nneamaka","family":"Echendu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James O.","family":"Akpeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Oji-Onuoha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uchenna","family":"Anyaoha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngozi","family":"Mbanefo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kingsley","family":"Ofodile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.09.046_b0005","unstructured":"World Health Organization. Polio eradication. https:\/\/www.who.int\/newsroom\/facts-in-pictures\/detail\/polio-eradication. Accessed 21 Feb 2023."},{"key":"10.1016\/j.vaccine.2023.09.046_b0010","unstructured":"World Health Organization. Control, elimination, eradication and re-emergence of infectious diseases: getting the message right. Bull WHO. www.who.int\/bulletin\/volumes\/84\/2\/editorial10206html\/en\/."},{"issue":"1","key":"10.1016\/j.vaccine.2023.09.046_b0015","first-page":"24","article-title":"Certifification of polio eradication: process and lessons learned","volume":"82","author":"Smith","year":"2004","journal-title":"Bull WHO"},{"key":"10.1016\/j.vaccine.2023.09.046_b0020","unstructured":"Nigeria achieves zero polio cases. Making Africa polio free at last, Available at jica.go.jp, accessed on April 3, 2023."},{"key":"10.1016\/j.vaccine.2023.09.046_b0025","unstructured":"Polio Endgame Strategy 2019 -2023: Eradication, integration, certification and containment. Geneva: World Health Organization; 2019 (WHO\/Polio\/19.04. Licence;CC BY-NC-SA 3.0 IGO."},{"key":"10.1016\/j.vaccine.2023.09.046_b0030","unstructured":"World Health Organization (WHO) Polio Vaccines: WHO Position Paper -June 2022, 97, 277-300."},{"key":"10.1016\/j.vaccine.2023.09.046_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2010.02.095","article-title":"the global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox","author":"Heinsbroek","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.09.046_b0040","unstructured":"World Health Organization. Cessation of routine oral polio vaccine (OPV) use after global polio eradication. Framework for National Policy Makers in OPVUsing Countries. WHO\/POLIO\/05.02.)."},{"key":"10.1016\/j.vaccine.2023.09.046_b0045","unstructured":"World Health Organization. Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol Rec 2006;81:137\u201344)."},{"issue":"9621","key":"10.1016\/j.vaccine.2023.09.046_b0050","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(08)60597-8","article-title":"Immunization against poliomyelitis: moving forward","volume":"371","author":"Ehrenfeld","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.09.046_b0055","unstructured":"Centers for Disease Control and Prevention. What are the Types of Polio Vaccine? https:\/\/www.cdc.gov\/vaccines\/vpd\/polio\/public\/. Accessed 2 April 2023."},{"key":"10.1016\/j.vaccine.2023.09.046_b0060","unstructured":"Polio Global initiative 2023: A Critical Year for polio eradication efforts in northern Nigeria \u2013 GPEI."},{"key":"10.1016\/j.vaccine.2023.09.046_b0065","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1016\/j.vaccine.2014.08.053","article-title":"Parental acceptance of inactivated polio vaccine in southeast nigeria: a qualitative cross-sectional intervention study","volume":"32","author":"Tagbo","year":"2014","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.vaccine.2023.09.046_b0070","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1016\/j.vaccine.2008.09.014","article-title":"influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants","volume":"26","author":"Hu","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2023.09.046_b0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1086\/508427","article-title":"Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico","volume":"195","author":"Dayan","year":"2007","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.09.046_b0080","doi-asserted-by":"crossref","first-page":"F24","DOI":"10.1136\/fn.83.1.F24","article-title":"Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth","volume":"83","author":"Linder","year":"2000","journal-title":"Arch Disease Childhood-Fetal Neonatal Edition"},{"key":"10.1016\/j.vaccine.2023.09.046_b0085","unstructured":"World Health Organization (WHO) Maternal and neonatal Tetanus zelimination strategies. 2022."},{"key":"10.1016\/j.vaccine.2023.09.046_b0090","doi-asserted-by":"crossref","unstructured":"Etti M, Calvert A, Galiza E, Lim S, Khalil A, Le Doare K, Heath PT. Maternal vaccination: a review of current evidence and recommendations. Am J Obstet Gynecol. 2022 Apr;226(4):459-474. doi: 10.1016\/j.ajog.2021.10.041. Epub 2021 Nov 11. PMID: 34774821; PMCID: PMC8582099.","DOI":"10.1016\/j.ajog.2021.10.041"},{"key":"10.1016\/j.vaccine.2023.09.046_b0095","doi-asserted-by":"crossref","unstructured":"David S. Khoury, Deborah Cromer, Arnold Reynaldi, Timothy E. Schlub, Adam K. Wheatley, Jennifer A. Juno, Kanta Subbarao, Stephen J. Kent, James A. Triccas, and Miles P. Davenport.\u2009Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Nature Medicine 2021 1205\u20131211 https:\/\/doi.org\/10.1038\/s41591-021-01377-8.","DOI":"10.1038\/s41591-021-01377-8"},{"key":"10.1016\/j.vaccine.2023.09.046_b0100","article-title":"Immunity status against poliomylitis in germany: Determination of cut-off values in internation units","author":"Diedrich","year":"20022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2023.09.046_b0105","doi-asserted-by":"crossref","unstructured":"Jia S, tang R, Li G, Hu Y, Liang Q. The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines. BMC Infectious Diseases 2020;20:641 https:\/\/doi.org\/10.1186\/s12879-020-05348-1.","DOI":"10.1186\/s12879-020-05348-1"},{"key":"10.1016\/j.vaccine.2023.09.046_b0110","doi-asserted-by":"crossref","first-page":"e047445","DOI":"10.1136\/bmjopen-2020-047445","article-title":"Factors associated with incomplete immunization in children aged 12\u201323 months at subnational level, Nigeria: a cross sectional study","volume":"11","author":"Eze","year":"2021","journal-title":"BMC Open"},{"key":"10.1016\/j.vaccine.2023.09.046_b0115","unstructured":"Uchenna AA, Saleh JE, Saddiq, Eze OL, Ogbonna PE, et al Intensified Routine zimmunization (RI) Activities: A Strategy for Improving RI and AFP Surveillance outcomes; Lessons from Abia State Nigeria. J Community Med Public Health 2018:CMPH-132.doi:10.29011\/2577-2228\/100032."},{"key":"10.1016\/j.vaccine.2023.09.046_b0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF02752350","article-title":"Effect of passively transferred anti-poliovirus antibody on seroconversion","volume":"66","author":"Bavdekar","year":"1999","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.vaccine.2023.09.046_b0125","first-page":"163","article-title":"Evidence for efficient vertical transfer of maternal HIV-1 Envelope-Specific neutralizing antibodies but no association of such antibodies with reduced infant infection","volume":"64","author":"Omenda","year":"2013","journal-title":"JAIDS-J Acq Imm Def"},{"key":"10.1016\/j.vaccine.2023.09.046_b0130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajp.1350320106","article-title":"Progressive improvement in the transfer of maternal antibody across the order primates","volume":"32","author":"Coe","year":"1994","journal-title":"Am J Primatol"},{"key":"10.1016\/j.vaccine.2023.09.046_b0135","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3389\/fimmu.2014.00446","article-title":"Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies","volume":"5","author":"Niewiesk","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.09.046_b0140","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy649","article-title":"Impact of maternal antibody on the immunogeneity of inactivated polio vaccine in infants immunizaed with bivalent oral polio vaccine: implications for the Polio eradication endgame","author":"Gaensbauer","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.09.046_b0145","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1186\/s12879-020-05348-1","article-title":"the effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines","volume":"20","author":"Jia","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2023.09.046_b0150","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/1096-9071(200104)63:4<305::AID-JMV1006>3.0.CO;2-U","article-title":"Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine","volume":"63","author":"Sormunen","year":"2001","journal-title":"J Med Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2023.09.046_b0155","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.vaccine.2023.01.035","article-title":"Effect of maternal immunisation with multivalent vaccines containing inactivated poliovirus vaccine (IPV) on infant IPV immune response: a phase 4, multi-centre randomised trial","volume":"41","author":"Grassly","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.09.046_b0160","doi-asserted-by":"crossref","first-page":"38874","DOI":"10.1038\/srep38874","article-title":"Placental antibody transfer efficiency and maternal levels: specific for measles, coxsackievirus A16, enterovirus 71, poliomyelitis I-III and HIV-1 antibodies","volume":"6","author":"Fu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.09.046_b0165","unstructured":"World Health Organization. Poliomyelitis: Vaccine derive polio. 2017."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23011167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23011167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:30:14Z","timestamp":1759404614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23011167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":33,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0264410X23011167"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.09.046","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralizing anti-polio antibody titre in newborn babies in post-polio eradication period in Nigeria","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.09.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}